Thus, the downward pressure of pricing over the next 3-4 years is unlikely given the estimated steady net costs of GLP-1s for weight loss in conjunction with the projected increases in the number of patients eligible to receive AOMs 23
(I am a big advocate of spacing out doses for people who have reached their goal weight, OR who are taking GLP-1s primarily for a possible metabolic/anti-inflammatory benefit, and who want to keep their weight neutral.) But maintenance dosing after achieving a clinical response is a completely different concept from starting at a sub-therapeutic dose and hoping it works
Well-designed trials in autoimmune populations are needed to better understand these outstanding questions
But in Arizona, as in most states, Medicaid doesnt cover GLP-1s for obesity alone
Some GLP-1 agonists like Wegovy are approved for the treatment of obesity in those who have weight-related health conditions like high blood pressure or cholesterol
With the right treatment plan, pigmentation can be cleared permanentlybut only if you follow preventive care afterward